OBJECTIVES: Diminished soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) concentrations are associated with cardiovascular diseases. We have analyzed sTWEAK levels and its relation with expansion rate in subjects with abdominal aortic aneurysm (AAA). METHODS: sTWEAK levels were measured by ELISA. RESULTS: sTWEAK concentrations were diminished in small AAA (≤ 5 cm; 353 ± 12 pg/mL; n = 25, p = 0.03) and large AAA (>5 cm; 315 ± 21 pg/mL; n = 18, p = 0.004) compared with healthy subjects (411 ± 22 pg/mL; n=27). Moreover, sTWEAK concentrations were negatively associated with AAA size (r = -0.4; p = 0.008). sTWEAK was also negatively associated with AAA expansion rate with 5 years of follow-up (n = 79, r = -0.263; p = 0.031). Multivariate regression analysis revealed that sTWEAK levels were independently associated with AAA growth rate (β = -0.208; p = 0.046). CONCLUSIONS: sTWEAK plasma levels were decreased in subjects with AAA and were independently related with AAA expansion rate indicating that this protein could be a novel diagnostic and prognostic biomarker of AAA.
OBJECTIVES: Diminished soluble tumornecrosis factor-like weak inducer of apoptosis (sTWEAK) concentrations are associated with cardiovascular diseases. We have analyzed sTWEAK levels and its relation with expansion rate in subjects with abdominal aortic aneurysm (AAA). METHODS: sTWEAK levels were measured by ELISA. RESULTS: sTWEAK concentrations were diminished in small AAA (≤ 5 cm; 353 ± 12 pg/mL; n = 25, p = 0.03) and large AAA (>5 cm; 315 ± 21 pg/mL; n = 18, p = 0.004) compared with healthy subjects (411 ± 22 pg/mL; n=27). Moreover, sTWEAK concentrations were negatively associated with AAA size (r = -0.4; p = 0.008). sTWEAK was also negatively associated with AAA expansion rate with 5 years of follow-up (n = 79, r = -0.263; p = 0.031). Multivariate regression analysis revealed that sTWEAK levels were independently associated with AAA growth rate (β = -0.208; p = 0.046). CONCLUSIONS: sTWEAK plasma levels were decreased in subjects with AAA and were independently related with AAA expansion rate indicating that this protein could be a novel diagnostic and prognostic biomarker of AAA.
Authors: Valvanera Fernández-Laso; Cristina Sastre; Jose M Valdivielso; Angels Betriu; Elvira Fernández; Jesús Egido; Jose L Martín-Ventura; Luis M Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2016-01-04 Impact factor: 8.237
Authors: Ana Belen Sanz; Maria Dolores Sanchez-Niño; Susana Carrasco; Felix Manzarbeitia; Olga Ruiz-Andres; Rafael Selgas; Marta Ruiz-Ortega; Carmen Gonzalez-Enguita; Jesus Egido; Alberto Ortiz Journal: PLoS One Date: 2012-10-15 Impact factor: 3.240
Authors: Carlos Tarín; Valvanera Fernández-Laso; Cristina Sastre; Julio Madrigal-Matute; Mónica Gómez; Carlos Zaragoza; Jesús Egido; Linda C Burkly; Jose L Martín-Ventura; Luis M Blanco-Colio Journal: J Am Heart Assoc Date: 2014-08-04 Impact factor: 5.501
Authors: Luis M Beltrán; Rocío Muñoz Hernández; Rebeca S de Pablo Bernal; José S García Morillo; Jesús Egido; Manuel Leal Noval; Sara Ferrando-Martinez; Luis M Blanco-Colio; Miguel Genebat; José R Villar; Rafael Moreno-Luna; Juan Antonio Moreno Journal: PLoS One Date: 2014-03-04 Impact factor: 3.240